Gossamer Bio, Inc.

Biotechnology • Healthcare • San Diego, CA, United States • GOSS (NMS)

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Stock Performance (90 Days)

Data through Dec 24, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Oppenheimer Confident in Positive PROSERA Trial Readout in February 2026 for Gossamer Bio (GOSS) - Yahoo Finance

Yahoo Finance • Dec 15

Gossamer Bio: High Risk Binary Approaches (NASDAQ:GOSS) - Seeking Alpha

Seeking Alpha • Dec 19

The Truth About Gossamer Bio Inc (GOSS): Tiny Stock, Massive Drama – Is It Worth the Hype? - AD HOC NEWS

AD HOC NEWS • Jan 4

Gossamer Bio (NASDAQ:GOSS) Stock Price Down 3.6% - What's Next? - MarketBeat

MarketBeat • Dec 30

Gossamer Bio stock outlook positive as seralutinib trial nears completion - Investing.com

Investing.com • Nov 13

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Gossamer Bio, Inc. had layoffs?

No layoff events have been recorded for Gossamer Bio, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does Gossamer Bio, Inc. have?

Gossamer Bio, Inc. has approximately 144 employees.

What industry is Gossamer Bio, Inc. in?

Gossamer Bio, Inc. operates in the Biotechnology industry, within the Healthcare sector.

Is Gossamer Bio, Inc. a publicly traded company?

Yes, Gossamer Bio, Inc. is publicly traded under the ticker symbol GOSS on the NMS. The company has a market capitalization of approximately $0.80 billion.

Where is Gossamer Bio, Inc. headquartered?

Gossamer Bio, Inc. is headquartered in San Diego, CA, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.